LEADER 00562nam# 22001693i 450 001 SUN0085326 005 20110922111809.470 100 $a20110922f2006 |0engc50 ba 101 $aeng 102 $aCH 105 $a|||| ||||| 200 1 $aAbstracts. 461 1$1001SUN0085322$12001 $aInternational congress of mathematicians Madrid 2006$1205 $a[Zurich] : European mathematical society$b[2006-2007]$1210 $dvol. ; 24 cm$1215 $aTit. della copertina. 801 $aIT$bSOL$c20181109$gRICA 912 $aSUN0085326 996 $aAbstracts$9725233 997 $aUNICAMPANIA LEADER 04294nam 2200517 450 001 9910830907803321 005 20230808205335.0 010 $a3-527-69441-2 010 $a3-527-69443-9 010 $a3-527-69439-0 035 $a(CKB)4330000000010660 035 $a(EBL)4649428 035 $a(MiAaPQ)EBC4649428 035 $a(OCoLC)957318452 035 $a(EXLCZ)994330000000010660 100 $a20160906h20162016 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $2rdacontent 182 $2rdamedia 183 $2rdacarrier 200 00$aBiomedical nanomaterials /$fedited by Yuliang Zhao and Youqing Shen 210 1$aWeinheim, Germany :$cWiley-VCH,$d2016. 210 4$dİ2016 215 $a1 online resource (501 p.) 300 $aDescription based upon print version of record. 311 $a3-527-33798-9 320 $aIncludes bibliographical references at the end of each chapters and index. 327 $aCover; Title Page; Copyright; Contents; List of Contributors; Chapter 1 Pharmacokinetics and Pharmacodynamics (PK/PD) of Bionanomaterials; 1.1 Introduction; 1.2 Commonly Utilized NMs in Pharmaceutical Research; 1.2.1 Natural NMs; 1.2.1.1 Lipid-Based NMs; 1.2.1.2 Protein-Based NMs; 1.2.1.3 Polysaccharide-Based NMs; 1.2.2 Synthetic NMs; 1.2.2.1 Diversity of Synthetic NMs in Forms; 1.2.2.2 Drug Release Behaviors; 1.2.3 Inorganic NMs; 1.2.4 Other NMs; 1.3 In vivo Biodistribution and the Evolving Targeting Principles for NMs; 1.3.1 Organ Distribution versus Cell-Specific Targeting 327 $a1.3.2 Targeting Delivery Strategies1.4 Processing NMs by the Biological Systems; 1.4.1 Anatomic Basis of NMs' in vivo Biodistribution Behavior; 1.4.2 Factors Affecting in vivo Biodistribution of NMs; 1.4.2.1 Size; 1.4.2.2 Zeta Potential; 1.4.2.3 Shape and Deformability; 1.4.2.4 Hydrophilicity and Hydrophobicity; 1.4.3 Metabolism and Elimination of NMs; 1.4.3.1 Common Metabolism; 1.4.3.2 Degradable versus Nondegradable NMs; 1.4.3.3 Free Drug versus Drug Encapsulated by NMs; 1.5 Rational Design of Long-Circulating NMs; 1.5.1 NMs with Optimal Physicochemical Characters 327 $a1.5.2 Surface Modification to Improve the Intrinsic Features of NMs1.6 Mathematic Simulation of NM-Mediated Cancer Drug Delivery; 1.6.1 Progress: From Experiment to Simulation; 1.6.2 Compartment Models for PK Assessment of NMs; 1.6.3 Physiologically Based Compartment Models; 1.6.3.1 Protocols of Building a PBPK Model for NMs; 1.6.3.2 Examples; 1.6.4 Brief Summary; 1.7 Experimental PK Data of the Applied NMs; 1.7.1 PK Data of NMs Without Drugs; 1.7.2 PK Differences Between Drugs Encapsulated by Different NMs; 1.7.3 Reciprocal Blood and Tissue PK 327 $a1.7.4 PK Differences Between Different Components of the Drug-NM System1.7.5 PK Variations Among Different Routes of Administration; 1.8 Perspectives; 1.8.1 Development of NMs; 1.8.2 Pharmacokinetic Study and Model Development; References; Chapter 2 Targeted Dendrimers for Cancer Diagnosis and Therapy; 2.1 Introduction; 2.2 Targeted Dendrimers for Cancer Therapy; 2.2.1 Low Molecular Weight Ligand-Modified Dendrimers; 2.2.1.1 Folic Acid-Modified Dendrimers; 2.2.1.2 Carbohydrate-Modified Dendrimers; 2.2.1.3 Biotin-Modified Dendrimers; 2.2.1.4 Riboflavin-Modified Dendrimers 327 $a2.2.1.5 Estrogen-Modified Dendrimers2.2.2 Macromolecular Ligand-Modified Dendrimers; 2.2.2.1 Antibody-Modified Dendrimers; 2.2.2.2 Transferrin (Tf)- and Lactoferrin (Lf)-Modified Dendrimers; 2.2.2.3 EGF- and Fibroblast Growth Factor (FGF)-Modified Dendrimers; 2.2.2.4 Peptide-Modified Dendrimers; 2.2.2.5 Aptamer-Modified Dendrimers; 2.2.2.6 Hyaluronic Acid (HA)-Modified Dendrimers; 2.2.3 Dual-Targeting Ligand-Modified Dendrimers; 2.3 Targeted Dendrimers for Cancer Diagnosis; 2.3.1 Targeted Dendrimers in CT; 2.3.2 Targeted Dendrimers in SPECT; 2.3.3 Targeted Dendrimers in MRI 327 $a2.3.4 Targeted Dendrimers in NIR Fluorescence Imaging 606 $aBiomedical materials 615 0$aBiomedical materials. 676 $a610.28 702 $aZhao$b Yuliang 702 $aShen$b Youqing 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910830907803321 996 $aBiomedical nanomaterials$92181871 997 $aUNINA